A Study to Evaluate SAR441566 Efficacy and Safety in Adults With Rheumatoid Arthritis
Completed · Phase 2 · NCT06073093
Conditions: Rheumatoid Arthritis
At a glance
- Research payments reported, 2025
- $1.4M
- U.S. investigators named
- 19
- Sites paid
- 21
- Planned or actual enrollment
- 264
About the trial
- Sponsor
- Sanofi
- Tested
- SAR441566 (drug), Placebo (drug)
- Dates
- Started 2023-11-07; completion 2025-07-02
- Results posted
- Not yet
This is a parallel group, Phase 2, randomized, double-blind, placebo controlled, 5-arm, international, multicenter, 12-week proof of concept, dose finding study. It is designed to assess efficacy and safety of treatment with SAR441566 for 12 weeks. It will be conducted in male and female adult participants with moderate-to-severe rheumatoid arthritis (RA) not adequately controlled on methotrexate (MTX) and biologic/targeted synthetic disease modifying anti-rheumatic drug (DMARD) naive. Study treatment includes investigational medicinal product (IMP: SAR441566 or placebo) added-on to a background therapy of MTX. Study details include a run-in period (4 to 6 weeks) before randomization to d…
From ClinicalTrials.gov, last updated 2025-07-11. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Sanofi US Services Inc. reported $1.4M in research payments for this study in 2025 (69 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Wonil Lee, M.D. Specialist · North Hollywood, CA
- Eric C. Lee, M.D. Specialist · Upland, CA
- John Carter, MD Rheumatology · Tampa, FL
- Emilio Pando, MD Internal Medicine · Miramar, FL
- Shanmugapriya Reddy, MD Rheumatology · Riverview, FL
- Jigar Shah, M.D. Rheumatology · Margate, FL
- Pilar F. Trueba, MD Family Medicine · Doral, FL
- Guillermo J. Valenzuela, MD Specialist · Plantation, FL
- Jane H. Box, MD Rheumatology · Charlotte, NC
- Gordon K. Lam, MD Rheumatology · Charlotte, NC
- Hillary E. Norton, M.D. Rheumatology · Santa Fe, NM
- Alan Kivitz, MD Rheumatology · Duncansville, PA
- Maria E. Chirino-socias, MD Rheumatology · San Juan, PR
- Gregory W. Niemer, M.D. Rheumatology · Summerville, SC
- Jeffrey A. Henderson, M.D., M.P.H. Internal Medicine · Rapid City, SD
- Shariq I. Chudhri, D.O. Rheumatology · Fort Worth, TX
- Michelle Eisenberg, D.O. Rheumatology · Houston, TX
- Fehmida Zahabi, MD Rheumatology · Plano, TX
- Jonathan G. Meiman, MD Family Medicine · Madison, WI
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Morristown Medical Center, NJ $366,445
- Prolato Research Llc $134,559
- Iris Research and Development LLC $133,275
- Ann & Robert H Lurie Childrens Hospital of Chicago, IL $125,000
- Labcorp Clinical Research $122,148
- Clinical Research of West Florida $88,269
- Arthritis and Osteoporosis Consulta of the Carolinas $61,086
- Innovia Research Center Inc $58,594
- Altoona Center for Clinical Research PC Corp $53,014
- Hillary E Norton MD PC Inspire Santa Fe Medical Group $33,381
- Arizona Arthritis Rheumatology Research PLLC $32,321
- Caribbean Medical Research Center L $31,219
- Corazon Usa Llc Dba Life Clinical Trials $29,600
- Amicis Research Center Llc $23,880
- Black Hills Center for American Indian Health $14,673
- Djl Clinical Research $13,798
- $7,787
- Future Care Solution Llc $7,300
- Sonia Martinez Innovia Research Center Inc $6,257
- Articularis Healthcare Group $5,550
- Inland Rheumatology Clinical Trials Inc $4,517
- Trinity Universal Research Associat $3,800
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.